Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 81 points (-0.5%) at 15,762 as of Thursday, Dec. 12, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,157 issues advancing vs. 1,771 declining with 147 unchanged. The Health Services industry currently sits down 0.4% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include Community Health Systems ( CYH), down 2.9%, Mindray Medical International Limited ADR r ( MR), down 2.6%, Catamaran ( CTRX), down 1.4%, Varian Medical Systems ( VAR), down 1.3% and Aetna ( AET), down 0.8%. A company within the industry that increased today was Boston Scientific ( BSX), up 1.3%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Quest Diagnostics ( DGX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Quest Diagnostics is down $0.82 (-1.5%) to $54.38 on heavy volume. Thus far, 1.8 million shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $54.15-$55.16 after having opened the day at $55.04 as compared to the previous trading day's close of $55.20. Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $8.5 billion and is part of the health care sector. The company has a P/E ratio of 11.3, below the S&P 500 P/E ratio of 17.7. Shares are up 0.6% year to date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Quest Diagnostics a buy, 4 analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, notable return on equity, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Quest Diagnostics Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.